Table 1.
Patient characteristics.
| n=41 | ||
|---|---|---|
| Age (years) | ||
| Median (range) | 40 (24-57) | |
| Lesion sites | ||
| Left, n (%) | 18 (43.9) | |
| Right, n (%) | 23 (56.1) | |
| T stage | ||
| T1, n (%) | 7 (17.1) | |
| T2, n (%) | 22 (53.7) | |
| T3, n (%) | 9 (22.0) | |
| T4, n (%) | 3 (7.3) | |
| N stage | ||
| N0, n (%) | 4 (9.8) | |
| N1, n (%) | 19 (46.3) | |
| N2, n (%) | 12 (29.3) | |
| N3, n (%) | 6 (14.6) | |
| Clinical stage | ||
| II A, n (%) | 4 (9.8) | |
| II B, n (%) | 13 (31.7) | |
| III A, n (%) | 16 (39.0) | |
| III B, n (%) | 2 (4.9) | |
| III C, n (%) | 6 (14.6) | |
T-stage, clinical tumor stages; N-stage, clinical node stages; AJCC, American Joint Committee on Cancer (8th); ER, estrogen receptor negative; PR, progesterone receptor negative; HER2, human epidermal growth factor receptor 2.